INIsabel Neckermann

Isabel Neckermann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Isabel Neckermann has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Abiha Abdullah

    Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

    2 shared publications
  • Amaan Rahman

    Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

    2 shared publications
  • Charbel Elias

    Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

    2 shared publications
  • Christopher Kaltenmeier

    Department of Surgery, Georgetown University, Washington D.C., USA

    2 shared publications
  • Eishan Ashwat

    Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

    2 shared publications
  • Hao Liu

    J.C. Walter Jr. Transplant Center and Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA

    2 shared publications

Latest Publications

  • Open Access

    An Electronic Frailty Index Is Associated with Outcomes in Older Adults Receiving CAR-T Therapy

    by Justine P. Enns, Mark R. Korst, Nora Horick, Isabel Neckermann, Olivia Y. Cheung, Bharati Kochar, Ariela R. Orkaby, Matthew J Frigault, Jeremy S Abramson, Areej El-Jawahri, et al.

    Predicting outcomes for older adults undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy is critical. Frailty is associated with poor outcomes, but can be difficult to measure in clinical practice. We retrospectively analyzed patients age ≥65 years receiving commercial CAR-T at Mass General Brigham for multiple myeloma and B-cell non-Hodgkin lymphoma. We calculated an electronic frailty index (eFI), a validated, automated frailty score (0.3=very frail). We evaluated associations of eFI (robust/prefrail vs frail vs very frail) with overall survival (OS), event-free (death, progression, or new treatment) survival (EFS), toxicity (cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS)), and days alive and out of hospital in the first 30 days (DAOH) using regression models controlling for confounders. Among 260 patients (median age: 73 years [range 65-91]), 10% were robust, 25% prefrail, 28% frail, and 37% very frail. In multivariable analyses, being frail was not associated with OS (hazard ratio [HR] 1.22, p=0.45) or EFS (HR=1.39, p=0.14), but very frail patients had significantly worse OS (HR=1.64, p<0.05) and EFS (HR=2.02, p<0.01). Both frail and very frail patients, respectively, had higher odds of grade 3+ toxicity (odds ratio [OR]=3.28, p<0.05; OR=4.84, p<0.01) and fewer DAOH (β= -2.37, p = 0.03; β= -3.79, p<0.01). The eFI identifies frail and very frail patients with higher risk for grade 3+ CRS/ICANS and increased healthcare utilization. Very frail patients are especially high-risk with poor OS and EFS. The eFI holds promise as an automated CAR-T risk-stratification tool.

    • 1 March 2026
      • Vol. 40  (3) , e70488
    Open Access

    Optimizing Liver Transplant Allocation for Hepatocellular Carcinoma: Development and Validation of a Survival Benefit-Based Model.

    by Hao Liu, Isabel Neckermann, Jason Mial-Anthony, Charbel Elias, Abiha Abdullah, Vrishketan Sethi, Christopher Kaltenmeier, Amaan Rahman, Eishan Ashwat, Packiaraj Godwin, et al.

    Liver transplantation (LT) is the only curative option for patients with unrespectable hepatocellular carcinoma (HCC). In the United States. current organ allocation policies grant the same priority to patients with tumors within the Milan criteria. This uniform approach leads to higher waitlist dropout among candidated with more advanced tumors of with more aggressive tumor biology. A model to stratify HCC candidates into different risk groups could optimize organ allocation by providing priority to patients within transplantable criteria but at increased risk of dropout. Data from 30,565 adult HCC LT candidates within the Scientific Registry of Transplant Recipients (SRTR) (2002-2022) were used. Inclusion criteria were age ≥18 years and tumors within Milan criteria. Recipients of previous transplants, multi-visceral grafts, and those with missing exception applications for HCC were excluded. The population was randomly divided into development (n = 15,282) and validation (n = 15,283) cohorts. The primary outcome was 5-year LT survival benefit, defined as the difference in survival with and without LT. C-MELD 3.0, serum AFP, and tumor burden score (TBS) were the strongest predictors of LT survival benefit. The HCC-Liver Transplant Survival Benefit model was defined as HCC-LTSB = 0.65 × (C-MELD 145 3.0 - 6) + 1.99 × (TBS - 2.25) + 0.68 × log2(AFP). Validation demonstrated strong performance (Pearson's r = 0.93; 95% CI: 0.93-0.94; R2 = 0.87; C-index = 0.91). The HCC-LTSB model accurately predicted the survival benefit provided by LT in candidates listed with unresectable HCC within UNOS criteria.

  • Open Access

    Optimizing Liver Transplant Allocation for Hepatocellular Carcinoma: Development and Validation of a Survival Benefit‐Based Model

    by Hao Liu, Isabel Neckermann, Jason Mial‐Anthony, Charbel Elias, Abiha Abdullah, Vrishketan Sethi, Christopher Kaltenmeier, Amaan Rahman, Eishan Ashwat, Packiaraj Godwin, et al.

    Introduction: Liver transplantation (LT) is the only curative option for patients with unrespectable hepatocellular carcinoma (HCC). In the United States. current organ allocation policies grant the same priority to patients with tumors within the Milan criteria. This uniform approach leads to higher waitlist dropout among candidated with more advanced tumors of with more aggressive tumor biology. A model to stratify HCC candidates into different risk groups could optimize organ allocation by providing priority to patients within transplantable criteria but at increased risk of dropout. Methods: Data from 30,565 adult HCC LT candidates within the Scientific Registry of Transplant Recipients (SRTR) (2002–2022) were used. Inclusion criteria were age ≥18 years and tumors within Milan criteria. Recipients of previous transplants, multi‐visceral grafts, and those with missing exception applications for HCC were excluded. The population was randomly divided into development ( n = 15,282) and validation ( n = 15,283) cohorts. The primary outcome was 5‐year LT survival benefit, defined as the difference in survival with and without LT. Results: C‐MELD 3.0, serum AFP, and tumor burden score (TBS) were the strongest predictors of LT survival benefit. The HCC‐Liver Transplant Survival Benefit model was defined as HCC‐LTSB = 0.65 × (C‐MELD 145 3.0 − 6) + 1.99 × (TBS − 2.25) + 0.68 × log2(AFP). Validation demonstrated strong performance (Pearson's r = 0.93; 95% CI: 0.93–0.94; R 2 = 0.87; C‐index = 0.91). Conclusion: The HCC‐LTSB model accurately predicted the survival benefit provided by LT in candidates listed with unresectable HCC within UNOS criteria.